Letter to the Editor
I thank Dr Murnion for her timely update regarding the definition and treatment of neuropathic pain.1
Despite the rewording, the new definition by the International Association for the Study of Pain (IASP) may still be over-inclusive by attempting to encompass a heterogenous constellation of syndromes and conditions with poorly understood pathophysiology.2 This has significant ramifications and causes confusion over the pharmaceutical management of neuropathic pain. For example, while gabapentinoids can be beneficial for postherpetic neuralgia and diabetic neuropathy, they do not appear to be better than placebo in sciatica,3,4 yet all these conditions are called neuropathic pain under IASP terminology.
The IASP recommended duloxetine, tricyclic antidepressants, pregabalin and gabapentin as first-line drugs.5 However, Australian guidelines still recommend amitriptyline first-line, pregabalin and gabapentin second-line, and duloxetine as a second- or third-line consideration.6
These differences are important in clinical practice. Amitriptyline and duloxetine are not subsidised by the Pharmaceutical Benefits Scheme (PBS) for neuropathic indications. Pregabalin and gabapentin are only PBS-subsidised when prescribed for refractory neuropathic pain unable to be controlled by other drugs. It is unclear what the ‘other drugs’ are, although for pregabalin, the Pharmaceutical Benefits Advisory Committee (PBAC) approval documents for neuropathic pain suggest these drugs may include amitriptyline and gabapentin.7 Nevertheless, PBS subsidy for both gabapentinoids is not for first-line drug therapy. The fact that these two drugs are the only PBS-subsidised drugs for neuropathic pain with poorly defined criteria may inadvertently result in a lower threshold for prescribing them.
After PBS listing there was greater than expected use of pregabalin for neuropathic pain and a higher than expected discontinuation rate after the first prescription. A subcommittee of PBAC concluded:
‘Prescribing of pregabalin in clinical practice may not be optimal. A large number of patients do not have the dose of pregabalin up-titrated and persistence to therapy is poor.’8
Some of this prescribing could be related to attempts to use pregabalin for treating sciatica as neuropathic pain.
There are increasing concerns gabapentinoids are being misused.9,10 The UK has restricted them as Class C controlled drugs effective from April 2019.11 Pregabalin appears to be highly lucrative in the Australian market leading to attempts at an early application for PBS listing before patent expiry (and associated legal proceedings).12 Given the lack of efficacy of gabapentinoids in certain conditions still classified as neuropathic pain, I urge a review of prescribing indications and careful rewording of PBS-authority requirements.
Orthopaedic surgeon, Meadowbank, Qld
- Murnion BP. Neuropathic pain: current definition and review of drug treatment. Aust Prescr 2018;41:60-3.
- International Association for the Study of Pain. IASP terminology. Pain terms. Neuropathic pain. Updated 2017 Dec 14. [cited 2018 Nov 5]
- Mathieson S, Maher CG, McLachlan AJ, Latimer J, Koes BW, Hancock MJ, et al. Trial of pregabalin for acute and chronic sciatica. N Engl J Med 2017;376:1111-20.
- Enke O, New HA, New CH, Mathieson S, McLachlan AJ, Latimer J, et al. Anticonvulsants in the treatment of low back pain and lumbar radicular pain: a systematic review and meta-analysis. CMAJ 2018;190:E786-93.
- Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol 2015;14:162-73.
- NPS MedicineWise. Neuropathic pain: diagnosis and treatment today. Medicinewise News 2018 Feb 5. [cited 2018 Nov 5]
- Pharmaceutical Benefits Scheme. Pregabalin, capsules, 25 mg, 75 mg, 150 mg and 300 mg, Lyrica® – March 2012. Public summary document, March 2012 PBAC Meeting. [cited 2018 Nov 5].
- Pharmaceutical Benefits Scheme. Pregabalin: 24 month predicted versus actual analysis. Public release document, October 2015 DUSC Meeting. [cited 2018 Nov 5]
- Smith RV, Havens JR, Walsh SL. Gabapentin misuse, abuse, and diversion: a systematic review. Addiction 2016;111:1160-74.
- Cairns R, Schaffer AL, Ryan N, Pearson SA, Buckley NA. Rising pregabalin use and misuse in Australia: trends in utilization and intentional poisonings. Addiction 2018 Aug 11 [Epub ahead of print].
- Mayor S. Pregabalin and gabapentin become controlled drugs to cut deaths from misuse. BMJ 2018;363:k4364.
- Federal Court of Australia. Warner-Lambert Company LLC v Apotex Pty Limited  FCAFC 58. [cited 2018 Nov 5]
- Treede RD, Rief W, Barke A, Aziz Q, Bennett MI, Benoliel R, et al. A classification of chronic pain for ICD-11. Pain 2015;156:1003-7.
- Day R. Off-label prescribing. Aust Prescr 2013;36:5-7.
The Editorial Executive Committee welcomes letters, which should be less than 250 words. Before a decision to publish is made, letters which refer to a published article may be sent to the author for a response. Any letter may be sent to an expert for comment. When letters are published, they are usually accompanied in the same issue by any responses or comments. The Committee screens out discourteous, inaccurate or libellous statements. The letters are sub-edited before publication. Authors are required to declare any conflicts of interest. The Committee's decision on publication is final.